Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial ...

Travere Therapeutics restructures to boost financial health, expands the kidney therapy pipeline, and sees rapid growth for ...

A humanized approach to pet wellness defines the current market. Owners increasingly choose familiar chewable supplements for ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

NEW YORK, Aug. 11, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hum ...

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Earth's Best, Once Upon a Farm, and Plum Organics earned top scoresA new California law helps consumers figure out whether ...

The medical stock then cleared its 50-day moving average within a cup base on Monday after the Food and Drug Administration ...

BioCryst Pharmaceuticals BCRX is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The ...

Sanuwave is a medical technology company that develops and commercializes its UltraMIST system, a non-contact, low-frequency ...

If it does rescind the finding, regulations on vehicle and power-plant emissions, which Mr Zeldin claims cost “$1trn or more ...